The ATAD1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ATAD1 gene in the human HEK293T cell line. This polyclonal format delivers a heterogeneous pool of ATAD1-deficient cells, reducing biases associated with clonal selection and offering a robust loss-of-function model. The knockout is achieved via CRISPR/Cas9-mediated gene disruption, resulting in abrogation of ATAD1 protein expression. This product serves as a versatile tool for investigating mitochondrial homeostasis, protein quality control, and fission dynamics in a readily transfectable epithelial context.
HEK293T cells are human embryonic kidney epithelial cells immortalized with sheared adenovirus 5 DNA and stably expressing the SV40 large T antigen. This background confers exceptional transfectability and supports high-level protein expression and viral production, making them a workhorse for cell biology and biochemical studies. Their epithelial origin provides a defined genetic and metabolic framework, though it should be noted that they differ from primary neuronal cells in which ATAD1-related pathologies manifest. Nonetheless, the HEK293T environment permits controlled dissection of ATAD1-mediated pathways.
ATAD1 encodes a mitochondrial outer membrane AAA+ ATPase that functions as a dislocase, extracting mislocalized tail-anchored proteins to prevent proteotoxic stress. It interacts with DRP1 to facilitate mitochondrial fission. Upstream, mitochondrial stress signals and the putative regulator PGC-1?? activate ATAD1. Downstream, ATAD1 targets DRP1 and mislocalized tail-anchored proteins, while physically interacting with DRP1, MFF, and mitochondrial outer membrane translocase subunits. Key fission pathway components include DRP1, FIS1, MFF, MFN1, and OPA1, all linked to ATAD1 function. Loss of ATAD1 disrupts protein extraction and DRP1-mediated fission, altering mitochondrial morphology.
In the HEK293T context, ATAD1 knockout cells enable precise investigation of mitochondrial quality control mechanisms without neuronal-specific complexities. The loss of ATAD1 disrupts extraction of mislocalized proteins, triggering proteotoxic stress and aberrant mitochondrial fission. The polyclonal population may better reflect the cellular heterogeneity seen in pathological states. Researchers can use these cells to model ATAD1-associated encephalopathy by introducing patient-derived ATAD1 mutations and assessing mitochondrial dysfunction through elevated-magnitude assays. The high transfectability facilitates complementation studies to validate ATAD1 function and test rescue of mutant phenotypes.
Typical applications include Western blotting to confirm ATAD1 depletion and monitor downstream targets like DRP1; immunofluorescence microscopy using mitochondrial markers (e.g., TOM20, cytochrome c) to evaluate fission and network morphology; mitochondrial fractionation to analyze protein localization; co-immunoprecipitation to assess ATAD1 interaction with DRP1 or MFF; and ATPase activity assays to monitor enzyme function. These cells are also suitable for drug screening to identify modulators of mitochondrial dynamics and for studying the kinetics of mitochondrial protein import. For technical inquiries or additional product details, please contact Ascent Research.
